vs
Journey Medical Corp（DERM）与REDWOOD TRUST INC（RWT）财务数据对比。点击上方公司名可切换其他公司
REDWOOD TRUST INC的季度营收约是Journey Medical Corp的1.6倍（$25.9M vs $16.1M），REDWOOD TRUST INC净利率更高（77.2% vs -7.8%，领先85.0%），Journey Medical Corp同比增速更快（27.3% vs -6.1%），过去两年Journey Medical Corp的营收复合增速更高（11.0% vs -41.0%）
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
Redwood Trust Inc是总部位于美国的专业房地产投资信托公司，主营住宅与商业抵押贷款、抵押贷款支持证券及房地产信贷类资产的投资管理，核心业务覆盖住宅抵押贷款发放、商业地产信贷和投资服务，客户以机构投资者和房地产市场参与者为主。
DERM vs RWT — 直观对比
营收规模更大
RWT
是对方的1.6倍
$16.1M
营收增速更快
DERM
高出33.4%
-6.1%
净利率更高
RWT
高出85.0%
-7.8%
两年增速更快
DERM
近两年复合增速
-41.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $25.9M |
| 净利润 | $-1.2M | $20.0M |
| 毛利率 | — | — |
| 营业利润率 | -2.8% | — |
| 净利率 | -7.8% | 77.2% |
| 营收同比 | 27.3% | -6.1% |
| 净利润同比 | -182.0% | 402.6% |
| 每股收益（稀释后） | $-0.04 | $0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DERMRWT
| Q4 25 | $16.1M | $25.9M | ||
| Q3 25 | $17.0M | $15.0M | ||
| Q2 25 | $15.0M | $13.8M | ||
| Q1 25 | $13.1M | $27.9M | ||
| Q4 24 | $12.6M | $27.6M | ||
| Q3 24 | $14.6M | $25.5M | ||
| Q2 24 | $14.9M | $67.4M | ||
| Q1 24 | $13.0M | $74.5M |
净利润DERMRWT
| Q4 25 | $-1.2M | $20.0M | ||
| Q3 25 | $-2.3M | $-7.7M | ||
| Q2 25 | $-3.8M | $-98.5M | ||
| Q1 25 | $-4.1M | $16.1M | ||
| Q4 24 | $1.5M | $-6.6M | ||
| Q3 24 | $-2.4M | $14.8M | ||
| Q2 24 | $-3.4M | $15.5M | ||
| Q1 24 | $-10.4M | $30.3M |
毛利率DERMRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
营业利润率DERMRWT
| Q4 25 | -2.8% | — | ||
| Q3 25 | -9.0% | -9.0% | ||
| Q2 25 | -19.2% | -679.0% | ||
| Q1 25 | -25.3% | 80.2% | ||
| Q4 24 | 17.7% | -1.3% | ||
| Q3 24 | -19.8% | 86.1% | ||
| Q2 24 | -19.7% | 30.3% | ||
| Q1 24 | -77.4% | 41.3% |
净利率DERMRWT
| Q4 25 | -7.8% | 77.2% | ||
| Q3 25 | -13.6% | -51.4% | ||
| Q2 25 | -25.3% | -712.0% | ||
| Q1 25 | -31.0% | 57.8% | ||
| Q4 24 | 12.1% | -24.0% | ||
| Q3 24 | -16.3% | 58.1% | ||
| Q2 24 | -22.6% | 23.0% | ||
| Q1 24 | -80.1% | 40.6% |
每股收益（稀释后）DERMRWT
| Q4 25 | $-0.04 | $0.11 | ||
| Q3 25 | $-0.09 | $-0.08 | ||
| Q2 25 | $-0.16 | $-0.76 | ||
| Q1 25 | $-0.18 | $0.10 | ||
| Q4 24 | $0.10 | $-0.08 | ||
| Q3 24 | $-0.12 | $0.09 | ||
| Q2 24 | $-0.17 | $0.10 | ||
| Q1 24 | $-0.53 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.1M | $255.7M |
| 总债务越低越好 | $25.3M | — |
| 股东权益账面价值 | $31.9M | $982.6M |
| 总资产 | $94.6M | $23.7B |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资DERMRWT
| Q4 25 | $24.1M | $255.7M | ||
| Q3 25 | $24.9M | $226.3M | ||
| Q2 25 | $20.3M | $302.0M | ||
| Q1 25 | $21.1M | $259.9M | ||
| Q4 24 | $20.3M | $245.2M | ||
| Q3 24 | $22.5M | $253.7M | ||
| Q2 24 | $23.9M | $275.6M | ||
| Q1 24 | $24.1M | $275.4M |
总债务DERMRWT
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | $1.7B |
股东权益DERMRWT
| Q4 25 | $31.9M | $982.6M | ||
| Q3 25 | $25.9M | $999.0M | ||
| Q2 25 | $19.2M | $1.1B | ||
| Q1 25 | $21.5M | $1.2B | ||
| Q4 24 | $20.1M | $1.2B | ||
| Q3 24 | $10.9M | $1.2B | ||
| Q2 24 | $11.3M | $1.2B | ||
| Q1 24 | $13.0M | $1.2B |
总资产DERMRWT
| Q4 25 | $94.6M | $23.7B | ||
| Q3 25 | $85.2M | $22.6B | ||
| Q2 25 | $81.2M | $21.3B | ||
| Q1 25 | $85.0M | $19.9B | ||
| Q4 24 | $80.2M | $18.3B | ||
| Q3 24 | $64.0M | $18.4B | ||
| Q2 24 | $65.2M | $16.5B | ||
| Q1 24 | $66.6M | $15.1B |
负债/权益比DERMRWT
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | 1.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.3M | $-10.1B |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | -504.15× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DERMRWT
| Q4 25 | $-6.3M | $-10.1B | ||
| Q3 25 | $-2.4M | $-2.7B | ||
| Q2 25 | $-942.0K | $-2.1B | ||
| Q1 25 | $-2.8M | $-2.0B | ||
| Q4 24 | $2.2M | $-5.9B | ||
| Q3 24 | $-1.2M | $-2.1B | ||
| Q2 24 | $-5.2M | $-2.0B | ||
| Q1 24 | $-5.0M | $-954.2M |
现金转化率DERMRWT
| Q4 25 | — | -504.15× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -120.92× | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | -140.86× | ||
| Q2 24 | — | -126.56× | ||
| Q1 24 | — | -31.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
RWT
暂无分部数据
